Abstract
Background: Prostate cancer (PCa) is an epithelial malignant tumor that occurs in the urinary system with high incidence and is the second most common cancer among men in the world. Thus, it is important to screen out potential key biomarkers for the pathogenesis and prognosis of PCa. The present study aimed to identify potential biomarkers to reveal the underlying molecular mechanisms. Methods: Differentially expressed genes (DEGs) between PCa tissues and matched normal tissues from The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) dataset were screened out by R software. Weighted gene co-expression network analysis was performed primarily to identify statistically significant genes for clinical manifestations. Protein–protein interaction (PPI) network analysis and network screening were performed based on the STRING database in conjunction with Cytoscape software. Hub genes were then screened out by Cytoscape in conjunction with stepwise algorithm and multivariate Cox regression analysis to construct a risk model. Gene expression in different clinical manifestations and survival analysis correlated with the expression of hub genes were performed. Moreover, the protein expression of hub genes was validated by the Human Protein Atlas database. Results: A total of 1,621 DEGs (870 downregulated genes and 751 upregulated genes) were identified from the TCGA-PRAD dataset. Eight prognostic genes [BUB1, KIF2C, CCNA2, CDC20, CCNB2, PBK, RRM2, and CDC45] and four hub genes (BUB1, KIF2C, CDC20, and PBK) potentially correlated with the pathogenesis of PCa were identified. A prognostic model with good predictive power for survival was constructed and was validated by the dataset in GSE21032. The survival analysis demonstrated that the expression of RRM2 was statistically significant to the prognosis of PCa, indicating that RRM2 may potentially play an important role in the PCa progression. Conclusion: The present study implied that RRM2 was associated with prognosis and could be used as a potential therapeutic target for PCa clinical treatment.
Highlights
Prostate cancer (PCa), one of the most common neoplasms worldwide, is ranked fourth among all cancer types with an incidence of 7.1% (Bray et al, 2018) and has been reported to be the second leading cause of cancer death among men (Siegel et al, 2018)
The survival analysis demonstrated that the expression of regulatory subunit M2 (RRM2) was statistically significant to the prognosis of PCa, indicating that RRM2 may potentially play an important role in the PCa progression
The present study implied that RRM2 was associated with prognosis and could be used as a potential therapeutic target for PCa clinical treatment
Summary
Prostate cancer (PCa), one of the most common neoplasms worldwide, is ranked fourth among all cancer types with an incidence of 7.1% (Bray et al, 2018) and has been reported to be the second leading cause of cancer death among men (Siegel et al, 2018). The detection of serum prostate-specific antigen (PSA) has been considered a common method to screen prostate cancer in the clinic. Due to its low specificity and significant limitations, it is difficult to make an early diagnosis with PSA. Prostate cancer (PCa) is an epithelial malignant tumor that occurs in the urinary system with high incidence and is the second most common cancer among men in the world. The present study aimed to identify potential biomarkers to reveal the underlying molecular mechanisms
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
